Research
Hormonal
Tirzepatide (10-15 mg) produces greater mean weight loss than semaglutide (2.4 mg) in head-to-head comparisons, achieving reductions of up to 20.9%.
Tirzepatide is a weekly injection that targets two hormones (GIP and GLP-1) to maximize weight loss, often resulting in ~20% body weight reduction. It requires slow dose escalation to manage stomach side effects.
StrongSupportsHIGH confidence
SURMOUNT-1 observed mean reductions in baseline body weight of 19.5% and 20.9% with tirzepatide doses of 10 and 15 mg/d, respectively, compared with a 3.1% for placebo.
Why this rating
Based on Phase 3 SURMOUNT-1 trial results.
Source
Evolving Approaches for Pharmacological Therapy of Obesity
Ariana M. Chao et al. · The Annual Review of Pharmacology and Toxicology · 2024
narrative_reviewCited 15×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →